The most effective strategy to improve public health is to identify a clearly defined, high frequency health threat and take systematic steps to reduce the risks it poses.
This premature, fake, media-driven endorsement may tempt many PTSD sufferers to give Ecstasy a try on their own, before knowing if it works and the potential harms.
When it comes to drugs, the United States has always had a split personality and a racist tilt.
Sleeping pills are to be used short-term and only after the patient has been briefed on all the many problems they frequently cause.
New research indicates one Psilocybin trip, lasting a mere eight hours, can reduce anxiety and depression in about 80% of cancer patients.
Benzodiazepines have been in widespread use for fifty years, but the clinical trials of these drugs were short-term and their long-term safety was never established.
I often equate the motives and methods of drug companies and drug cartels, but Pharma’s moral bankruptcy can surprise even me.
During the recent election, recreational pot was approved by voters in California, Massachusetts, Maine, and Nevada – losing only in Arizona.
It is not in Pharma’s DNA to miss any opportunity to find profit in patient suffering, even if its own products are at the root of the suffering.
When it comes to rating drug danger, Kratom seems to be something of a mild pussycat, while prescription opioids are the most ferocious of tigers.
Ketamine is now being given a third possible starring role as a new miracle drug for depression.
Carfentanil, a veterinary medicine used for things like anesthetizing elephants, has recently hit the streets and is causing large clusters of overdose and death.
The honor that comes from the Sackler family’s philanthropy is tainted by dishonor in knowing their fortune was accumulated via the OxyContin epidemic.
The exponential growth of addiction to prescription opioids offers a classic example of selfish corporate greed swamping any vestige of corporate conscience.
Two conflicting DSM-5 and DSM IV diagnoses have radically different implications for treatment planning and for prognosis.
One of the most common mistakes in a psychiatric diagnosis is ignoring the possibility that a substance problem could be causing the presenting symptoms.
Most people take benzodiazepines long-term, in addictively high doses, and for the wrong reasons.
A seemingly small change in DSM-5 disguises what is really a giant conceptual leap in the behavioral addiction arena.